FDA approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting.
John C. Byrd grew up in Augusta, a town of 2,000 or so in northeastern Arkansas.
FDA Approves Varubi for Chemotherapy-Induced Nausea and Vomiting
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
FDA has withdrawn a proposed rule that called for standardized testing for detecting and identifying asbestos in talc-containing cosmetic products.
The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?
Harvey A. Risch, professor emeritus and senior research scientist at Yale School of Public Health, said he was named chair of the President’s Cancer Panel. Risch will succeed Elizabeth M. Jaffee, who was appointed by President Joe Biden in January 2023.
The U.S. House of Representatives unanimously passed the Mikaela Naylon Give Kids A Chance Act, a bill to accelerate pediatric cancer treatments and expand access to life-saving therapies for children battling rare diseases.
Scott Gottlieb, a former FDA commissioner, said a recent decision by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices’ to change its recommendation for when children should receive the hepatitis B vaccine is another sign of the ACIP’s diminished credibility as a scientific authority.
